share_log

bluebird bio | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

bluebird bio | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

bluebird bio | NT 10-Q：季報延遲披露公告
美股SEC公告 ·  08/14 19:14

牛牛AI助理已提取核心訊息

bluebird bio, Inc. has filed a notification of late filing with the Securities and Exchange Commission (SEC), indicating that it will not be able to submit its Quarterly Report on Form 10-Q for the period ended June 30, 2024, by the prescribed due date of August 14, 2024. The delay is attributed to the company's ongoing efforts to restate its financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. This restatement process has also affected the timely filing of its Annual Report for 2023 and the First Quarter Report for 2024. bluebird bio is working diligently to complete the restatement and file all outstanding reports as soon as possible. The company anticipates significant changes in its results of operations for the quarter ended June 30, 2024, compared to the same period in 2023, due to identified errors in lease and non-lease component accounting in agreements with contract manufacturing organizations. However, the company has stated that these errors are not expected to impact its cash position or revenue.
bluebird bio, Inc. has filed a notification of late filing with the Securities and Exchange Commission (SEC), indicating that it will not be able to submit its Quarterly Report on Form 10-Q for the period ended June 30, 2024, by the prescribed due date of August 14, 2024. The delay is attributed to the company's ongoing efforts to restate its financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. This restatement process has also affected the timely filing of its Annual Report for 2023 and the First Quarter Report for 2024. bluebird bio is working diligently to complete the restatement and file all outstanding reports as soon as possible. The company anticipates significant changes in its results of operations for the quarter ended June 30, 2024, compared to the same period in 2023, due to identified errors in lease and non-lease component accounting in agreements with contract manufacturing organizations. However, the company has stated that these errors are not expected to impact its cash position or revenue.
bluebird bio公司已向證券交易所委員會（SEC）提交了一份延遲報告的通知，表明該公司無法在規定的截止日期2024年8月14日前提交截至2024年6月30日的第10-Q表格的季度報告。延遲歸因於該公司爲重述截至2022年12月31日和2022年和2023年前三個季度的基本報表而進行的持續努力。該重述過程還影響了其2023年年度報告和2024年第一季度報告的按時提交。bluebird bio正在努力完成重述工作，儘快提交所有未完成的報告。該公司預計，與2023年同比，截至2024年6月30日的財務運營結果將有重大變化，這是由於存在於與合同製造組織的協議中的租賃和非租賃構成會計方面的錯誤所致。然而，該公司表示這些錯誤不會影響其現金狀況或營業收入。
bluebird bio公司已向證券交易所委員會（SEC）提交了一份延遲報告的通知，表明該公司無法在規定的截止日期2024年8月14日前提交截至2024年6月30日的第10-Q表格的季度報告。延遲歸因於該公司爲重述截至2022年12月31日和2022年和2023年前三個季度的基本報表而進行的持續努力。該重述過程還影響了其2023年年度報告和2024年第一季度報告的按時提交。bluebird bio正在努力完成重述工作，儘快提交所有未完成的報告。該公司預計，與2023年同比，截至2024年6月30日的財務運營結果將有重大變化，這是由於存在於與合同製造組織的協議中的租賃和非租賃構成會計方面的錯誤所致。然而，該公司表示這些錯誤不會影響其現金狀況或營業收入。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間